1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
June 2024 in “Journal of medical pharmaceutical and allied sciences” Orange pectin boosts probiotic growth, especially L. acidophilus.
13 citations
,
December 2009 in “Journal of the Peripheral Nervous System” TRPA1 and TRPV1 channels don't affect mechanotransduction in rat sinus hair follicles.
62 citations
,
November 2022 in “Acta Pharmaceutica Sinica B” The injectable hydrogel effectively speeds up chronic wound healing.
January 2025 in “Archives of Dermatological Research” 23 citations
,
November 2018 in “International Journal of Molecular Sciences” Deoxyshikonin helps wounds heal faster in diabetic mice.
November 2025 in “Frontiers in Pharmacology” Gentamicin-loaded exosomes improve healing of infected diabetic wounds in mice.
November 2025 in “Applied Research” Synthetic curcumin derivatives improve treatment for diabetes and cancer.
June 2023 in “International Journal of Clinical Research and Reports” Method B with propylene glycol is better for stable low-concentration DPCP solutions for alopecia areata.
January 1978 in “Clin-Alert” A document listed serious side effects from various drugs, including deaths and diseases, emphasizing the importance of being aware of drug side effects.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
88 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes” 61 citations
,
January 2013 in “International Journal of Biological Macromolecules” Combining DHT and EDC improves the strength and stability of PADM scaffolds for tissue engineering.
51 citations
,
October 2019 in “Cells” Baricitinib reduces inflammation and improves cell health in premature aging cells.
March 2002 in “Clin-Alert” In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” CD101 is highly effective in treating dermatophytosis in guinea pigs.
5 citations
,
April 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” A new therapy for a skin blistering condition has not been developed yet.
19 citations
,
August 2023 in “Experimental & Molecular Medicine” Blocking CXXC5 speeds up diabetic wound healing by improving blood vessel growth and skin repair.
22 citations
,
March 1999 in “International Journal of Clinical Practice” Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.
February 2026 in “Scientific Reports” Platycladi Cacumen may help treat hair loss by affecting certain biological pathways.
28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.
August 2018 in “Dermatologic Surgery” 8 citations
,
July 2023 in “Frontiers in Pharmacology” Cepharanthine shows promise as a COVID-19 treatment.
CaBP1 and CaBP2 are important for continuous hearing by preventing inactivation of calcium currents in ear cells, with CaBP2 also able to restore hearing when reintroduced.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
January 2024 in “Journal of Natural Remedies” Alkaloids show promise in treating cholangiocarcinoma by effectively targeting cancer cells.
81 citations
,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.